Latest news with #BE
Yahoo
4 days ago
- Business
- Yahoo
ComEd Receives Approval for Beneficial Electrification Plan 2, Continuing to Advance Transportation Electrification in Illinois
Investment of $168 million over three years will support EV purchases and charging infrastructure advancements CHICAGO, May 29, 2025--(BUSINESS WIRE)--ComEd today announced that the Illinois Commerce Commission (ICC) has approved its second Beneficial Electrification (BE) Plan, investing approximately $168 million over a three-year period beginning in 2026. The continuation of ComEd's BE funding marks a significant step forward in ComEd's commitment to advancing electric vehicle (EV) adoption and reducing emissions in northern Illinois. Building on its current $231 million investment in beneficial electrification, deployed from 2023 through 2025, ComEd will invest an additional $168 million between 2026-2028 through BE Plan 2 to help residential and non-residential customers transition to and take advantage of electric vehicles. Since February of 2024, ComEd has incentivized the purchase and installation of nearly 5,000 public and private EV charging ports (Level 2 and Fast Chargers) and the purchase or lease of nearly 1,000 new and pre-owned electric fleet vehicles. More than 70% of the rebates awarded have gone to low-income customers or business and public sector organizations located in, or primarily serving, low-income and Equity Investment Eligible Communities (EIECs). Over this same period, Illinois has seen EV registrations grow three to four times faster than the nation as a whole. "The shift to EVs is a major milestone on the road to Illinois' clean energy future, and it is part of a broader effort to electrify more of our region's energy system," said Gil C. Quiniones, ComEd President and CEO. "Through the expansion of our Beneficial Electrification programs, ComEd is helping to reduce carbon emissions, improve air quality, and enable all communities to enjoy the benefits and opportunities that flow from the global energy transformation." The approval of ComEd's BE Plan 2 follows the successful implementation of ComEd's first BE Plan, which was approved in 2023 under the guidance of the Climate and Equitable Jobs Act (CEJA). Signed into law by Governor J.B. Pritzker in 2021, CEJA aims to combat climate change by leveraging Illinois' clean electricity grid and promoting beneficial electrification across the state. "Illinois is committed to decarbonizing the transportation sector, and ComEd's BE Plan 2 plays a crucial role in enabling more electric vehicle adoption in the state," said Megha Lakhchaura, State EV Officer of Illinois. "By expanding charging infrastructure and providing incentives from the state and key partners like ComEd, we are making EV adoption more accessible and practical for residents and businesses alike." Key components of ComEd's second Beneficial Electrification Plan include: Residential EV Charger and Installation Program: $11 million, over three years, to offer rebates of up to $2,500 per household to support the purchase and installation of residential Level 2 electric vehicle chargers. Business and Public Sector EV Purchase Program: $82 million, over three years, to offer rebates for the purchase or lease of new or pre-owned fleet EVs of all weight classes. Business and Public Sector Make-Ready Program: $44 million, over three years, to offer rebates for covering costs associated with making sites ready for public or private Level 2 of DC Fast Charging equipment. Customer Education and Awareness Program: $11 million, over three years, to fund multiple efforts to empower and support customers to make informed decisions about vehicle electrification and charging infrastructure deployment. This includes free access to ComEd support tools including Fleet Electrification Assessments, EV Toolkits and training programs for municipalities interested in achieving "EV Ready" status, and free Fleet Electrification Assessments, among others. Research and Development Program: $11 million, over three years, to evaluate and demonstrate the impact of new transportation and electrification technologies. Portfolio Program: $9 million, over three years, to fund a variety of initiatives spanning across multiple programs, to support a successful deployment of BE Plan 2 as a whole. Projects located in, or primarily serving, low income or EIECs, will be eligible for higher rebate amounts, and will receive more than 50% of the BE Plan 2 budget. Exact rebate amounts may be adjusted in response to demand over the course of the BE Plan 2 timeline. EVs provide a variety of benefits for customers. Not only do they offer fuel and maintenance cost savings and performance benefits, but communities can experience broad environmental improvements from reduced tailpipe emissions. Additionally, electrifying transportation—especially vehicle fleets—can create tangible benefits for all communities and families across northern Illinois, including health benefits in communities which have traditionally borne the brunt of climate change and air pollution. "Reducing vehicle emissions is one of the most effective ways to improve air quality and public health," said Brian Urbaszewski, Director of Environmental Health Programs at Respiratory Health Association. "Given current uncertainty with other sources of funding that foster zero-emission transportation, ComEd's continued investment in its Beneficial Electrification Plan is now even more critical in helping cut harmful pollutants, leading to cleaner air and healthier communities across northern Illinois." ComEd's BE Plan 2 was developed in close collaboration with multiple stakeholders, including environmental organizations, community groups and industry experts to ensure equitable access to electrification benefits. The continued efforts in 2026 will build upon the existing resources and tools ComEd has already launched to support customer education and EV adoption including, the ComEd EV Toolkit, EV Ambassador Program, EV Readiness program, EV Load Capacity Map, Fleet Electrification Assessments, EV Service Provider Network, EV Dealership Network and more. For more information on ComEd's second BE Plan and available resources and programs offered by ComEd, please visit ComEd is a unit of Chicago-based Exelon Corporation (NASDAQ: EXC), a Fortune 200 energy company serving more than 10.7 million electricity and natural gas customers—the largest number of customers in the U.S. ComEd powers the lives of more than 4 million customers across northern Illinois, or 70 percent of the state's population. For more information, visit and connect with the company on Facebook, Instagram, LinkedIn, X and YouTube. View source version on Contacts ComEdMedia Relations312-394-3500
Mid East Info
23-05-2025
- Business
- Mid East Info
Robots and Human-Centric AI Dazzle at Opening of BEYOND Expo 2025; Pioneering Asian tech unveiled as industry leaders call for global cooperation
Robots attract attention at BEYOND Expo 2025 Source: BEYOND Expo Macau, China: The 5 th BEYOND Expo opened it door to visitors today at The Venetian® Macao's Cotai Expo as over 800 pioneering Asian companies and tech leaders gathered to showcase leading innovations in robotics, human-centric AI, mixed reality and climate solutions under the theme 'Empowering Asia, Connecting the World'. VIPs and industry leaders from across Asia came together to share their perspectives about the importance of international cooperation, cross-cultural dialogue and globalization to create mutually beneficial economic and investment opportunities. Asian companies displayed pioneering tech across a wide range of sectors from AI, HealthTech, Clean Energy and Robotics to Lifestyle Tech, SportsTech, FinTech and more, wowing business owners, investors and dignitaries who had come to Macao for the Expo. Realising BEYOND Expo's vision of 'Empowering Asia, Bridging the World' the BGlobal Summit opened with a keynote from H.E. Djauhari Oratmangun, Indonesian Ambassador to China, who highlighted the growing economic and investment opportunities in Indonesia and across Asia. Takeo Kawamura – 76 th Chief Cabinet Secretary of Japan – highlighted the importance of international cooperation, cross-cultural dialogue, and Japan's evolving approach to globalization. Throughout the Expo's exhibitor booths and event stages, conversations focused on the need to leverage human-centered tech solutions to tackle global challenges. Xpeng Aeroht demonstrates AEROHT at BEYOND Expo 2025 Source: BEYOND Expo Panel sessions today included Green Building Conference; BGlobal Summit; Japan Tech Forum; Middle East-Asia Forum; Asia-Europe Tech Forum; International Industrial Design Forum; Founder Talk; Demo session; ORIGIN Southeast Asia Tech Forum; and SheTech Summit. Encouraging Innovation – BEYOND Expo Awards BEYOND Expo co-founders Jason Ho and Dr. Lu Gang presented BEYOND Best Choice awards to 25 companies. Since its inception in 2021, the BEYOND Awards have received more than 1,500 nominations, of which more than 200 innovative pioneers have been included in the list. This year's award combines technological breakthroughs, business potential, social value and other dimensions. In order to nurture startups, BEYOND Expo offers Innovation Awards to support entrepreneurs and discover outstanding individuals or technical products and services. The BEYOND Impact Awards honor companies that are driving meaningful change in the realms of environment, society, economy, and technology in line with the United Nation' 17 Sustainable Development Goals. Other awards include Gen Z Innovators: The New Force, which focuses on Gen Z entrepreneurs in China looking out towards Asia, BEYOND Medical Technology Excellence Awards and BEYOND Healthy Living Products Innovation Awards which focuses on excellence in medical technology companies and health consumption products. Visitors flock to BEYOND Expo 2025 Source: BEYOND Expo Visit BEYOND Expo 2025 at The Venetian® Macao's Cotai Expo BEYOND Expo 2025 is being held at The Venetian® Macao's Cotai Expo. Since opening, Cotai Expo has been a leading conference, meetings and exhibition venue in Macao, and is one of the largest MICE venues in Asia, with approximately 71,000 square metres of exhibition space. It is also part of Sands® Resorts Macao, which attracts top event planners from around the world due to its 150,000 square metres of MICE space, world-class entertainment venues, award-winning accommodation, spectacular recreation and leisure options, unrivalled shopping experiences, and dynamic dining options. Sands Resorts Macao's newest hotel, located within The Londoner® Macao, is Londoner Grand, which marks a bold new chapter in luxury for discerning travellers and event planners. A full list of participating companies can be found here: BEYOND EXPO 2025
Yahoo
14-05-2025
- Business
- Yahoo
BE Q1 Earnings Call: Solid Project Execution and Data Center Demand Drive Outperformance
Electricity generation and hydrogen production company Bloom Energy (NYSE:BE) announced better-than-expected revenue in Q1 CY2025, with sales up 38.6% year on year to $326 million. The company's full-year revenue guidance of $1.75 billion at the midpoint came in 1.2% above analysts' estimates. Its non-GAAP profit of $0.03 per share was significantly above analysts' consensus estimates. Is now the time to buy BE? Find out in our full research report (it's free). Revenue: $326 million vs analyst estimates of $291.4 million (38.6% year-on-year growth, 11.9% beat) Adjusted EPS: $0.03 vs analyst estimates of -$0.06 (significant beat) Adjusted EBITDA: $25.16 million vs analyst estimates of $12.76 million (7.7% margin, 97.2% beat) The company reconfirmed its revenue guidance for the full year of $1.75 billion at the midpoint Operating Margin: -5.8%, up from -20.8% in the same quarter last year Free Cash Flow was -$124.9 million compared to -$168.7 million in the same quarter last year Market Capitalization: $4.45 billion Bloom Energy's first quarter results were shaped by robust project execution and steady demand from key customer segments, particularly data centers and industrial clients. CEO KR Sridhar emphasized the company's ability to deliver on-site power solutions amid infrastructure constraints, noting that the grid's limitations have shifted customer attitudes: 'The debate is over—on-site power is now a necessity,' Sridhar stated. This shift was reflected in Bloom's strong project pipeline and improved service profitability, with management highlighting the impact of product mix and operational efficiency on margins. Looking ahead, management reiterated confidence in its full-year revenue and margin guidance, attributing this to continued diversification across sectors and geographies. Sridhar pointed to ongoing partnerships with utilities, expanding international efforts, and disciplined cost reduction initiatives as key components underpinning Bloom's outlook. Despite external headwinds such as tariffs, the company expects to offset cost pressures through operational improvements and supply chain resilience, with Sridhar maintaining, 'We are not going to pass it on to going to find ways to solve it.' Management attributed Bloom Energy's performance in the first quarter to a combination of resilient demand across core segments and operational improvements. The company's diversification and ability to adapt to evolving customer needs were central themes in the discussion. Data Center Project Momentum: Management highlighted ongoing strength in demand from AI-driven data centers, describing the sector as being in an 'investment super cycle' that is unlikely to slow in the near term. Bloom's on-site power solutions are increasingly viewed as essential due to grid limitations and rising energy needs. Industrial and Manufacturing Growth: The company reported continued activity among large-load manufacturing and semiconductor customers, citing growth in the U.S. industrial base and the critical need for reliable power for automated and AI-enabled factories. Management expects automation trends to further increase electricity intensity in this sector. International Expansion: Bloom's international business, especially in South Korea, remains strong, with targeted growth in Europe and Asia. Management reported focused efforts in Italy, Germany, the UK, and Taiwan, citing the unique value of Bloom's energy solutions in regions facing grid constraints. Operational Improvements: The company's product mix and 'level-loaded' manufacturing strategy contributed to higher gross margins. Service profitability improved for the fifth consecutive quarter, supported by technology upgrades and AI-assisted execution. Tariff and Supply Chain Management: Management stated that its U.S.-based manufacturing and diversified supply chain minimize exposure to tariffs and supply disruptions. Cost reduction remains a core focus, with ongoing projects to offset up to a 100-basis-point margin impact from tariffs without passing costs to customers. Looking ahead, Bloom Energy's management anticipates that diversified customer demand and disciplined cost control will underpin performance in the coming quarters. The company's outlook is shaped by structural trends in power demand, ongoing technology enhancements, and a resilient supply chain. On-Site Power Adoption: Management sees broad acceptance of on-site power as a necessity across data centers, manufacturing, and healthcare, driven by persistent grid constraints and increased electrification. Utility Partnerships and Market Diversification: The ongoing expansion of partnerships with utilities and entry into selected international markets are expected to provide additional growth avenues and reduce reliance on any single segment or geography. Cost Reduction Initiatives: The company's multi-year track record of double-digit cost reductions is expected to continue, mitigating external pressures such as tariffs and supporting margins even as Bloom scales operations. Andrew Percoco (Morgan Stanley): Asked about potential delays in project pipeline conversion and the impact of tariffs on margin guidance. Management reiterated confidence in meeting guidance, citing strong customer demand and detailed cost mitigation plans. Manav Gupta (UBS): Inquired whether partnerships with utilities or direct sales would drive more deployments in coming years. CEO Sridhar said both models are being pursued, with utility partnerships preferred for larger loads. Dushyant Ailani (Jefferies): Asked about margin sustainability and the sensitivity of tariff impacts if rates change. Management emphasized its conviction in the current guidance and its ability to adapt cost structure as needed. Colin Rusch (Oppenheimer): Questioned supply chain resilience for critical materials amid trade tensions. Sridhar stated that Bloom's supply chain is diversified and not reliant on China, with sources spread across multiple continents. Chris Dendrinos (RBC Capital Markets): Requested details on cost-saving strategies to offset tariffs. Management described a portfolio approach to cost reduction, involving technology improvements, simplification, and supply chain efficiencies reviewed at the executive level. In the coming quarters, the StockStory team will be watching (1) the pace of data center and industrial project conversions as infrastructure spending accelerates, (2) Bloom's ability to maintain or improve gross margins through ongoing cost reduction and product mix initiatives, and (3) progress in expanding utility partnerships and international sales, particularly in targeted European and Asian markets. The sustainability of service profitability and execution on backlog will also be important indicators of operational strength. Bloom Energy currently trades at a forward P/E ratio of 42.8×. In the wake of earnings, is it a buy or sell? See for yourself in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
Lifeless Bloom Energy Stock (BE) Flashes ‘Bullish Trading Signal,' Says Analyst
Although clean energy company Bloom Energy (BE) stock has cratered over the past few months, aggressive risk-takers have a contrarian opportunity in the short-medium term. Ultimately, BE stock exemplifies the classic showdown between narrative-based fundamentals (which are admittedly poor) versus the market's core demand profile for BE stock. I am bullish on Bloom, but my unconventional, options-focused thesis may not be suitable for risk-averse value hunters. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. As a conventional strategy, investors may choose to mostly ignore BE stock, and for entirely justifiable reasons. Sure, Bloom posted better-than-expected results for its latest first-quarter earnings report. However, the beat largely stemmed from nuances in project timing and a one-off customer settlement. In other words, such matters do not represent a basis for sustainable growth. Plus, management's reiteration of full-year guidance signaled no expectation for meaningful upward progress. The stock currently features an Underperform rating via TipRanks. However, arguably the most worrying sticking point is Bloom CFO Daniel Berenbaum's sudden departure after just 12 months in the job. Based on how the energy company framed the resignation, specifically by not discussing a transition period, there may have been difficulties related to the eventual parting of ways. Whatever the case, it's difficult for shareholders to swallow, adding to concerns for BE stock. Given the empirical data on demand and the confluence of factors surrounding the stock, I believe there is a risky but rational wager on the table. To clarify my approach, this is not intended to be a comprehensive analysis of Bloom Energy, its fuel-cell technology, or a detailed review of its Q1 results. That is beyond the purpose here. My focus is solely on demand and whether the market was a net buyer of BE stock or not. Everything else is secondary. Many analysts would likely view this methodology as overly simplistic or binary, and that is precisely the point. Their critiques highlight the core strength of this framework. Demand is among the few metrics that can be meaningfully compared across different market environments. In contrast, price and financial performance indicators — such as revenue and earnings — are often anchored to shifting contexts and thus lose comparability over time. By contrast, regardless of the prevailing conditions in prior periods, investors always had to be persuaded by certain factors to become net stock buyers. Put simply, while fear and greed fluctuate, these emotions remain among the few constants in market dynamics. Viewed through this lens, BE stock — like any security — can be categorized, quantified, and analyzed probabilistically, not merely through price movements but as evolving behavioral states. More specifically, analysts can track the conditions under which bearish sentiment transitions to bullish sentiment, and vice versa. In my view, this offers a far more robust and insightful approach than attempting to interpret the shifting narratives in the headlines. For BE stock, the reversal signal that flashed was that in the past 10 weeks, it printed a '3-7' sequence: three weeks of upside interspersed with seven weeks of downside, with a negative trajectory across the period. Historically, whenever this sequence flashes, there's been a 58.8% chance that the following week would see an upswing. This is a significant pattern because BE stock has a slightly negative bias as a baseline. On any given week, there's a 47.88% chance that a position entered at the beginning of the period will be profitable by the end of it. Thus, when the 3-7 flashes, the risk-reward asymmetry shifts from the bears to the bulls. Of course, there are no guarantees in market forecasting. However, assuming that the positive pathway wins out, traders would see a gradual rise toward the $18 level over the next 10 weeks. If the negative pathway wins out, BE may deflate toward the $15 level. For those wishing to capitalize on a struggling name that's in store for a rebound, traders may consider the 17/18 bull call spread expiring May 30, 2025. Arguably, this spread represents the most aggressive multi-leg options strategy that you can buy while still touching rationality. The above transaction involves buying the $17 call and simultaneously selling the $18 call, for a net debit paid of $50. Should BE stock rise through the short strike price of $18 at expiration, the maximum reward is also $50, a payout of 100%. Assuming again that the positive pathway wins out, based on median volatility trends, BE stock is projected to reach $17.82 over the next four weeks. That's the median projection, so the actual figure could be higher (or lower). That's the risk one takes with these low-cost, high-payout debit spreads. A more conservative trade is the 17/17.50 bull call spread expiring May 23. This transaction involves a net debit of $80, with a maximum reward of $70, or a payout of 87.5%. However, BE stock would be projected to reach $17.63 at expiration, thus eclipsing the short strike price. On Wall Street, BE stock carries a Moderate Buy consensus rating based on nine Buy, eight Hold, and two Sell ratings over the past three months. BE's average price target of $23.59 implies ~45% upside potential over the next twelve months. While the prevailing narrative around Bloom Energy may not be particularly favorable, it's important to remember that the market is driven by more than just stories. Ultimately, investors face a straightforward choice: to be net buyers of a security or not. At its core, the decision is that simple. In the case of BE stock, there has historically been a specific pattern of demand behavior that has preceded notable shifts in sentiment — shifts that stand out from the stock's typical statistical trends. Such insights are not easily gleaned from traditional fundamental analysis, which creates a potential opportunity for investors willing to take a contrarian stance. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-05-2025
- Health
- Yahoo
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, 'The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC' FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its TissueCypher Barrett's Esophagus test via two posters at the Digestive Disease Week® (DDW 2025) Annual Meeting, being held May 3-6 in San Diego. In addition to the product theater, Castle is collaborating with renowned gastrointestinal (GI) experts and the American Society for Gastrointestinal Endoscopy (ASGE) on several educational sessions highlighting the use of TissueCypher to improve the risk stratification and subsequent management of patients with Barrett's esophagus (BE). 'The compelling new data being presented at DDW 2025 underpins the important role that TissueCypher can play in identifying patients with BE at higher risk for progression to esophageal cancer,' said Emmanuel Gorospe, M.D., MPH, board-certified gastroenterologist and GI medical director at Castle Biosciences. 'By empowering clinicians to move beyond the traditional 'wait and see' approach, we're working to help enable more personalized surveillance and intervention strategies for BE patients that can potentially prevent cancer rather than simply trying to detect it early.' The following posters will be presented at DDW 2025 (all times Pacific Time). Posters will be available on the DDW ePosters site and to conference attendees in the DDW meeting planner and mobile app after 12:01 a.m. on the day of the poster's presentation. 1) Poster Su1466: The Tissue Systems Pathology Test Detected Presence of Missed Neoplasia in a Patient with Non-Dysplastic Barrett's Esophagus Presenter and Lead Author: Philip Woodworth, M.D., Sky Ridge Heartburn and Reflux Treatment Center and Institute of Esophageal and Reflux Surgery Session Type: Poster Session Session Title: Pancreatic and Esophageal Diseases Session #: 7105 Date & Time: Sunday, May 4, 12:30-1:30 p.m. 2) Poster Su1324: The Tissue Systems Pathology Test Provides Risk Stratification for Patients with Barrett's Esophagus Presenter and Senior Author: Charles Randall, M.D., Gastroenterology Research of San Antonio and University of Texas Health Science Center at San Antonio Session Type: Poster Session Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Biology and Fundamental Mechanisms, Epidemiology, Risk Factors, and Screening Session #: 7085 Session Date & Time: Sunday, May 4, 12:30-1:30 p.m. Visit Castle at DDW 2025For more information on the TissueCypher test and the posters above, please visit Castle at booth 1017; a complete list of Castle's activities at DDW 2025 can be found at Key events include the following: Product Theater The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC Expert physician panel convened by EndoscopyNow includes: Vivek Kaul, M.D., professor of medicine at University of Rochester Medical Center Harshit Khara, M.D., associate professor of medicine and director of endoscopy at Geisinger Medical Center Jennifer Kolb, M.D., M.S., assistant professor of medicine, Vatche and Tamar Manoukian Division of Digestive Diseases at the David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System Sri Komanduri, M.D., M.S., associate chief, division of gastroenterology and hepatology, and professor of medicine and surgery at Northwestern Feinberg School of Medicine Location: DDW Theater 1 Date & Time: Sunday, May 4, 2:45-3:30 p.m. AGA Research Forum: Advances in Screening and Risk Stratification in Barrett's Esophagus Presentation title: Clinical utility of tissue systems pathology (TSP-9) risk stratification in patients with and without a family history of Barrett's esophagus and/or esophageal cancer Presenter: Marcia (Mimi) Canto, M.D., MHS, professor of medicine at The Johns Hopkins University School of Medicine Session #: 5270 Date & Time: Tuesday, May 6, 10 a.m. ASGE Theater Talks1) Think BEyond the "Wait and See" paradigm for non-dysplastic Barrett's esophagus Presenter: Dan Lister, M.D., president and co-founder of the American Foregut Society and director of the Arkansas Heartburn Treatment Center Date & Time: Saturday, May 3, 11:30 a.m.-12 p.m. 2) The tissue systems pathology test detected presence of missed neoplasia in a patient with non-dysplastic Barrett's esophagus Presenter: Philip Woodworth, M.D., Sky Ridge Heartburn and Reflux Treatment Center and Institute of Esophageal and Reflux Surgery Date & Time: Monday, May 5, 12:15-12:45 p.m. About Digestive Disease Week® (DDW) Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), the meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at TissueCypher Barrett's Esophagus TestThe TissueCypher Barrett's Esophagus test is Castle's precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett's esophagus (BE). The TissueCypher Barrett's Esophagus test is indicated for use in patients with endoscopic biopsy confirmed BE that is graded non-dysplastic (NDBE), indefinite for dysplasia (IND) or low-grade dysplasia (LGD); its clinical performance has been supported by 16 peer-reviewed publications of BE progressor patients with leading clinical centers around the world. The test received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS) in March 2022. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. These forward-looking statements include, but are not limited to, statements concerning: TissueCypher's ability to (i) play an important role in identifying BE patients at higher risk for progression to esophageal cancer, (ii) empower clinicians and (iii) enable more personalized surveillance and intervention strategies for BE patients that help prevent cancer. The words 'believe,' 'can' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences, in to access your portfolio
